Oppenheimer Maintains Perform On Illumina Following 3Q14 Results
In a research report issued to investors today, Oppenheimer analyst Bret Jones maintained a Perform rating on Illumina (NASDAQ:ILMN) following the company’s fourth-quarter results, posting revenue of $481M (+35% y/y) and adjusted EPS of $0.77 compare to Oppenheimer’s in-line estimates of $450M and $0.56. No price target was provided.
Jones noted, “While the company continues to execute nearly flawlessly, we are concerned that growth in the key clinical segment will not evolve in a smooth, linear fashion.” The analyst added, “We are increasing our 2014 revenue and EPS estimates to be $1.85B and EPS of $2.64.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Bret Jones has a total average return of 1.4% and a 59.1% success rate. Jones is ranked #1698 out of 3337 analysts.